1
|
Salari G, Shadi A, Ahmadi A, Esfandyari J, Nikmanesh H. Targeted delivery of doxorubicin to B-cell lymphoma using monoclonal antibody-functionalized Chaetoceros biosilica. Sci Rep 2025; 15:16598. [PMID: 40360717 PMCID: PMC12075519 DOI: 10.1038/s41598-025-01504-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2025] [Accepted: 05/06/2025] [Indexed: 05/15/2025] Open
Abstract
The use of biogenic nanoparticles as targeted drug delivery systems has gained increasing attention for improving anticancer therapies. This study investigates the effectiveness of porous biosilica derived from the diatom Chaetoceros sp., functionalized with hydrophilic GPTMS, labeled with CD-19 antibody, and loaded with doxorubicin in targeting Raji cells, a B lymphoid cell line. Biosilica was extracted, purified, and modified for enhanced drug delivery. Characterization involved X-ray diffraction (XRD), Brunauer-Emmett-Teller (BET) analysis, zeta potential measurement, dynamic light scattering (DLS), Transmission Electron Microscopy (TEM), scanning electron microscopy (SEM), and Fourier-transform infrared (FT-IR) spectroscopy, followed by drug loading and release measurements. Cytotoxicity was assessed using the MTT assay and apoptosis tests, with Jurkat cells as non-target controls. Results confirmed successful GPTMS surface modification and revealed the amorphous structure of biosilica, with mean intraparticle pore sizes of 130 nm (BET). The drug loading capacity reached 53.92%. The system exhibited significant cytotoxic effects on Raji cells (IC50 = 0.1 mg/mL), with lower Jurkat cell survival (p < 0.05). Enhanced apoptosis was detected in Raji cells. These findings suggest the modified biosilica has substantial potential for targeted drug delivery, with the antibody enhancing attachment and release at target sites. Further investigation is needed to address biocompatibility and bioaccumulation for in vivo applications.
Collapse
Affiliation(s)
- Ghazal Salari
- Department of Biological Science and Technology, Persian Gulf University, Bushehr, 751691, Iran
| | - Ahmad Shadi
- Department of Biological Science and Technology, Persian Gulf University, Bushehr, 751691, Iran.
| | - Amirhossein Ahmadi
- Department of Biological Science and Technology, Persian Gulf University, Bushehr, 751691, Iran
| | - Javid Esfandyari
- The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
| | | |
Collapse
|
2
|
Gong Q, Zhu T, Zhang L, Wu H, Miao Y, Hu Y. Synthesis of AgInS 2 quantum dots loaded with celastrol for induction of apoptosis and autophagy in hepatocellular carcinoma cells. Discov Oncol 2025; 16:538. [PMID: 40238029 PMCID: PMC12003245 DOI: 10.1007/s12672-025-02332-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2025] [Accepted: 04/08/2025] [Indexed: 04/18/2025] Open
Abstract
Hepatocellular carcinoma (HCC) is a predominant form of liver cancer and one of the leading causes of cancer-related death globally. Therefore, there is an urgent need for innovative therapeutic strategies that target the molecular mechanisms underlying HCC progression and metastasis, aiming to improve treatment efficacy and patient survival. The natural product celastrol (Cel) has demonstrated inhibitory effects in various cancer cell lines. However, its clinical application has been hindered by high toxicity and a low safety threshold. Metal-free quantum dots (QDs), AgInS2 (AIS QDs) not only eliminate toxic risks associated with heavy metals but also exhibit high biocompatibility in the biomedical field. By developing AIS QD@Cel, an AIS QDs nano-delivery system for Cel, the cell selectivity and inhibitory effects of Cel on HCC were enhanced. Fourier-transform infrared spectroscopy (FTIR) analysis revealed that AIS QDs can interact with Cel via amide bonds. The encapsulation rate of AIS QDs to Cel reached 27.5%. AIS QD@Cel eliminated toxicity on 293T and enhanced inhibition on HCC cells by over 10 times. Furthermore, the western blotting and flow cytometry experiments showed that AIS QD@Cel promoted apoptosis and autophagy signal pathway. Finally, transcriptome sequencing revealed that AIS QD@Cel effect on HCC by regulating gene expression involved in critical signaling pathways that are implicated in the progression of cancer. This strategy holds the potential to increase safety threshold and clinical applicability of Cel, offering significant clinical value for the treatment of HCC patients.
Collapse
Affiliation(s)
- Qineng Gong
- Medical Research Center, Affiliated Hospital 2, Nantong University, Nantong, 226001, People's Republic of China
- Jiangsu Provincial Medical Key Discipline (Laboratory) Cultivation Unit, Medical Research Center, Nantong First People's Hospital, Nantong, 226001, People's Republic of China
| | - Tianyu Zhu
- Medical Research Center, Affiliated Hospital 2, Nantong University, Nantong, 226001, People's Republic of China
- Jiangsu Provincial Medical Key Discipline (Laboratory) Cultivation Unit, Medical Research Center, Nantong First People's Hospital, Nantong, 226001, People's Republic of China
| | - Linlin Zhang
- Department of Pharmacology, The First People's Hospital of Yancheng, Yancheng, 224000, People's Republic of China
- Department of Pharmacology, The Fourth Affiliated Hospital of Nantong University, Yancheng, 224000, People's Republic of China
| | - Hui Wu
- Department of Pharmacology, The First People's Hospital of Yancheng, Yancheng, 224000, People's Republic of China
- Department of Pharmacology, The Fourth Affiliated Hospital of Nantong University, Yancheng, 224000, People's Republic of China
| | - Yang Miao
- Department of Pharmacology, The First People's Hospital of Yancheng, Yancheng, 224000, People's Republic of China.
- Department of Pharmacology, The Fourth Affiliated Hospital of Nantong University, Yancheng, 224000, People's Republic of China.
| | - Ye Hu
- Department of Pharmacology, The First People's Hospital of Yancheng, Yancheng, 224000, People's Republic of China.
- Department of Pharmacology, The Fourth Affiliated Hospital of Nantong University, Yancheng, 224000, People's Republic of China.
| |
Collapse
|
3
|
Zuo H, Tao J, Wang M, Xie X, Sun M. A novel immunochemotherapy based on immunogenicity-activated and immunosuppression-reversed biomimetic nanoparticles. RSC Adv 2022; 12:28104-28112. [PMID: 36320259 PMCID: PMC9527569 DOI: 10.1039/d2ra04326b] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Accepted: 09/25/2022] [Indexed: 01/24/2023] Open
Abstract
Studies show that infiltrated myeloid-derived suppressor cells (MDSCs) are vital in the immunosuppressive tumor microenvironment and account for lymphoma refractoriness and recurrence. Here, we developed a biomimetic nanoplatform (PM-PLGA-DOX/GEM) in which platelet membranes (PM) wrap PLGA nanoparticles co-loaded with doxorubicin (DOX) and gemcitabine (GEM). PM-PLGA-DOX/GEM would accumulate in tumor tissues because of the enhanced permeation and retention (EPR) effect and the tumor cell-induced platelet aggregation (TCIPA) effect. GEM could eliminate the MDSCs in tumor tissues, thereby reversing the immunosuppressive tumor microenvironment. Furthermore, DOX could invoke the immunogenic cell death (ICD) of lymphoma cells. Consequently, numerous T cells were recruited and activated to improve the therapeutic effects. This study will offer a potential platform for clinical treatment of lymphoma and other solid tumors.
Collapse
Affiliation(s)
- Huaqin Zuo
- Department of Hematology, Northern Jiangsu People's Hospital Affiliated to Yangzhou UniversityYangzhouJiangsu225001P. R. China
| | - Junxian Tao
- Department of Endocrinology, Northern Jiangsu People's Hospital Affiliated to Yangzhou UniversityYangzhouJiangsu225001P. R. China
| | - Manli Wang
- Graduate School of Dalian Medical UniversityDalianLiaoning116044P. R. China
| | - Xiaoyan Xie
- Department of Hematology, Northern Jiangsu People's Hospital Affiliated to Yangzhou UniversityYangzhouJiangsu225001P. R. China
| | - Mei Sun
- Department of Hematology, Northern Jiangsu People's Hospital Affiliated to Yangzhou UniversityYangzhouJiangsu225001P. R. China
| |
Collapse
|
4
|
Wang J, Yang J, Kopeček J. Nanomedicines in B cell-targeting therapies. Acta Biomater 2022; 137:1-19. [PMID: 34687954 PMCID: PMC8678319 DOI: 10.1016/j.actbio.2021.10.024] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Revised: 09/29/2021] [Accepted: 10/14/2021] [Indexed: 02/08/2023]
Abstract
B cells play multiple roles in immune responses related to autoimmune diseases as well as different types of cancers. As such, strategies focused on B cell targeting attracted wide interest and developed intensively. There are several common mechanisms various B cell targeting therapies have relied on, including direct B cell depletion, modulation of B cell antigen receptor (BCR) signaling, targeting B cell survival factors, targeting the B cell and T cell costimulation, and immune checkpoint blockade. Nanocarriers, used as drug delivery vehicles, possess numerous advantages to low molecular weight drugs, reducing drug toxicity, enhancing blood circulation time, as well as augmenting targeting efficacy and improving therapeutic effect. Herein, we review the commonly used targets involved in B cell targeting approaches and the utilization of various nanocarriers as B cell-targeted delivery vehicles. STATEMENT OF SIGNIFICANCE: As B cells are engaged significantly in the development of many kinds of diseases, utilization of nanomedicines in B cell depletion therapies have been rapidly developed. Although numerous studies focused on B cell targeting have already been done, there are still various potential receptors awaiting further investigation. This review summarizes the most relevant studies that utilized nanotechnologies associated with different B cell depletion approaches, providing a useful tool for selection of receptors, agents and/or nanocarriers matching specific diseases. Along with uncovering new targets in the function map of B cells, there will be a growing number of candidates that can benefit from nanoscale drug delivery.
Collapse
Affiliation(s)
- Jiawei Wang
- Center for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT, United States; Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, United States
| | - Jiyuan Yang
- Center for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT, United States; Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, United States
| | - Jindřich Kopeček
- Center for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT, United States; Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, United States; Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, United States.
| |
Collapse
|
5
|
Synergistic antitumor efficacy of doxorubicin and gambogic acid-encapsulated albumin nanocomposites. Colloids Surf B Biointerfaces 2020; 196:111286. [DOI: 10.1016/j.colsurfb.2020.111286] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Revised: 07/18/2020] [Accepted: 07/27/2020] [Indexed: 01/22/2023]
|
6
|
Sangtani A, Petryayeva E, Susumu K, Oh E, Huston AL, Lasarte-Aragones G, Medintz IL, Algar WR, Delehanty JB. Nanoparticle–Peptide–Drug Bioconjugates for Unassisted Defeat of Multidrug Resistance in a Model Cancer Cell Line. Bioconjug Chem 2019; 30:525-530. [DOI: 10.1021/acs.bioconjchem.8b00755] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Ajmeeta Sangtani
- Fischell Department of Bioengineering, University of Maryland, College Park, Maryland 20742, United States
| | - Eleonora Petryayeva
- Department of Chemistry, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | | | - Eunkeu Oh
- KeyW Corporation, Hanover, Maryland 21076, United States
| | | | | | | | - W. Russ Algar
- Department of Chemistry, University of British Columbia, Vancouver, British Columbia V6T 1Z1, Canada
| | | |
Collapse
|
7
|
Chen D, Chen B, Yao F. Doxorubicin-Loaded PEG-CdTe Quantum Dots as a Smart Drug Delivery System for Extramedullary Multiple Myeloma Treatment. NANOSCALE RESEARCH LETTERS 2018; 13:373. [PMID: 30467726 PMCID: PMC6250610 DOI: 10.1186/s11671-018-2782-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Accepted: 10/31/2018] [Indexed: 05/19/2023]
Abstract
New drug treatments still do not improve the prognosis of extramedullary multiple myeloma (EMM) patients. Luckily, high-dose chemotherapy can raise the prognosis, but is intolerant to most patients because of drug cytotoxicity. Nanoparticles (NPs) are used as drug carriers to prolong drug circulation time, control drug release, reduce drug toxicity and bioavailability, and target specific sites. In this work, doxorubicin (DOX) was loaded in polyethylene glycol-modified cadmium telluride quantum dots (PEG-CdTe QDs). PEG-CdTe-DOX facilitated intracellular drug accumulation through polyethylene organizational compatibility and released DOX into the microenvironment in a pH-controlled manner, which enhanced the therapeutic efficacy and the apoptosis rate of myeloma cells (PRMI8226). PEG-CdTe-DOX improved the anti-tumor activity of DOX by regulating the protein expressions of apoptosis-associated genes. In summary, PEG-CdTe-DOX provides a specific and effective clinical treatment for EMM patients.
Collapse
Affiliation(s)
- Dangui Chen
- Department of hematology, Anqing Municipal Hospital, Anqing Hospital Affiliated to Anhui Medical University, Anqing, 246003, People's Republic of China
| | - Bing Chen
- Department of hematology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, People's Republic of China.
| | - Fusheng Yao
- Department of hematology, Anqing Municipal Hospital, Anqing Hospital Affiliated to Anhui Medical University, Anqing, 246003, People's Republic of China.
| |
Collapse
|